GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gensight Biologics SA (XPAR:SIGHT) » Definitions » Total Premiums Earned

Gensight Biologics (XPAR:SIGHT) Total Premiums Earned


View and export this data going back to 2016. Start your Free Trial

What is Gensight Biologics Total Premiums Earned?

Total Premiums Earned only applies to insurance companies.


Gensight Biologics Business Description

Traded in Other Exchanges
Address
74, rue du Faubourg Saint-Antoine, Paris, FRA, 75012
Gensight Biologics SA is a clinical-stage biotechnology group discovering and developing novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system. The company's pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence, and Optogenetics, to help preserve or restore vision in patients suffering from severe degenerative retinal diseases. The group's focus is on ophthalmology where it develops product candidates to restore eyesight to patients suffering from retinal diseases. The product candidate, LUMEVOQ, was developed using the MTS technology platform and is designed to treat LHON by restoring the function of retinal diseases resulting from mutations.